Prism Finds Funding From Japanese Government VC To Launch New Trials
This article was originally published in PharmAsia News
Executive Summary
Prism’s lead compound is already in-licensed by Eisai for cancer indications, and the startup is now looking for a partner for the compound’s fibrosis indications now that Phase I plans are in the works.
You may also be interested in...
Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan
YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.